For help on how to get the results you want, see our search tips.
1570 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Authorisation status
Authorised Remove Authorised filter
-
List item
Human medicine European public assessment report (EPAR): Taxotere (updated)
docetaxel, Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Prostatic Neoplasms; Stomach Neoplasms; Breast Neoplasms
Date of authorisation: 27/11/1995, Revision: 50, Authorised, Last updated: 24/03/2023 -
List item
Human medicine European public assessment report (EPAR): Myocet liposomal (previously Myocet) (updated)
doxorubicin hydrochloride, Breast Neoplasms
Date of authorisation: 13/07/2000, Revision: 24, Authorised, Last updated: 24/03/2023 -
List item
Human medicine European public assessment report (EPAR): Enspryng (updated)
satralizumab, Neuromyelitis Optica
Date of authorisation: 24/06/2021,
, Revision: 2, Authorised, Last updated: 24/03/2023
-
List item
Human medicine European public assessment report (EPAR): Tamiflu (updated)
oseltamivir, Influenza, Human
Date of authorisation: 20/06/2002, Revision: 42, Authorised, Last updated: 24/03/2023 -
List item
Human medicine European public assessment report (EPAR): Miglustat Dipharma (updated)
miglustat, Gaucher Disease
Date of authorisation: 18/02/2019,
, Revision: 5, Authorised, Last updated: 24/03/2023
-
List item
Human medicine European public assessment report (EPAR): Brukinsa (updated)
zanubrutinib, Waldenstrom Macroglobulinemia
Date of authorisation: 22/11/2021,
, Revision: 5, Authorised, Last updated: 24/03/2023
-
List item
Human medicine European public assessment report (EPAR): Truvelog Mix 30 (updated)
insulin aspart, Diabetes Mellitus
Date of authorisation: 25/04/2022,, 
, Revision: 1, Authorised, Last updated: 23/03/2023
-
List item
Human medicine European public assessment report (EPAR): Terrosa (updated)
teriparatide, Osteoporosis
Date of authorisation: 04/01/2017,, , Revision: 6, Authorised, Last updated: 23/03/2023
-
List item
Human medicine European public assessment report (EPAR): Upstaza (updated)
Eladocagene exuparvovec, Amino Acid Metabolism, Inborn Errors
Date of authorisation: 18/07/2022,, , 
, Revision: 3, Authorised, Last updated: 23/03/2023
-
List item
Human medicine European public assessment report (EPAR): Dupixent (updated)
dupilumab, Dermatitis, Atopic; Prurigo; Esophageal Diseases; Asthma; Sinusitis
Date of authorisation: 26/09/2017, Revision: 25, Authorised, Last updated: 23/03/2023 -
List item
Human medicine European public assessment report (EPAR): MabThera (updated)
rituximab, Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 02/06/1998, Revision: 58, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Ocrevus (updated)
ocrelizumab, Multiple Sclerosis
Date of authorisation: 08/01/2018, Revision: 16, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Kadcyla (updated)
trastuzumab emtansine, Breast Neoplasms
Date of authorisation: 15/11/2013, Revision: 15, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Vegzelma (updated)
bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 17/08/2022,, , Revision: 2, Authorised, Last updated: 22/03/2023
-
List item
Human medicine European public assessment report (EPAR): Polivy (updated)
polatuzumab vedotin, Lymphoma, B-Cell
Date of authorisation: 16/01/2020,, , 
, Revision: 5, Authorised, Last updated: 22/03/2023
-
List item
Human medicine European public assessment report (EPAR): Elebrato Ellipta (updated)
fluticasone furoate, umeclidinium bromide, vilanterol trifenatate, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 15/11/2017, Revision: 11, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Suliqua (updated)
insulin glargine, lixisenatide, Diabetes Mellitus, Type 2
Date of authorisation: 11/01/2017, Revision: 10, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Trelegy Ellipta (updated)
fluticasone furoate, umeclidinium bromide, vilanterol trifenatate, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 15/11/2017, Revision: 10, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Pradaxa (updated)
Dabigatran etexilate mesilate, Arthroplasty, Replacement; Venous Thromboembolism
Date of authorisation: 17/03/2008, Revision: 39, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Zynlonta (updated)
loncastuximab tesirine, Lymphoma, Large B-Cell, Diffuse; Lymphoma, B-Cell
Date of authorisation: 20/12/2022,, , Revision: 1, Authorised, Last updated: 22/03/2023
-
List item
Human medicine European public assessment report (EPAR): Simponi (updated)
Golimumab, Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid
Date of authorisation: 01/10/2009, Revision: 44, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Hexacima (updated)
hepatitis B surface antigen, Diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens Pertussis Toxoid Filamentous Haemagglutinin, poliovirus (inactivated) type 1 (Mahoney) type 2 (MEF-1) type 3 (Saukett), Haemophilus influenzae type b polysaccharide (Polyribosylribitol Phosphate) conjugated to Tetanus protein, Hepatitis B; Tetanus; Immunization; Meningitis, Haemophilus; Whooping Cough; Poliomyelitis; Diphtheria
Date of authorisation: 17/04/2013,
Date of refusal: 22/02/2013, Revision: 28, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): NovoRapid (updated)
insulin aspart, Diabetes Mellitus
Date of authorisation: 07/09/1999, Revision: 32, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Blincyto (updated)
blinatumomab, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 23/11/2015,, , Revision: 16, Authorised, Last updated: 22/03/2023
-
List item
Human medicine European public assessment report (EPAR): Xolair (updated)
omalizumab, Asthma; Urticaria
Date of authorisation: 25/10/2005, Revision: 45, Authorised, Last updated: 22/03/2023